Immune-cell SMN deficits complicate the meaning of recovery in spinal muscular atrophy
Disease-modifying therapy has rewritten the prognosis of spinal muscular atrophy, but the biology it exposes is proving harder to read. Crystal Jing Jing Yeo’s JCI commentary frames a central problem in the treated era: motor improvement does not necessarily mean full restoration of survival motor neuron, or SMN, function across all vulnerable tissues.
That question matters because SMN is not a motor-neuron-only protein. It is expressed broadly, and the commentary uses new data from Tapken, Rahmel-Stein, and colleagues to argue that cell type, developmental stage, and intrinsic SMN requirement all shape which tissues remain abnormal after treatment. In neonatal SMA mice, SMN expression was highest in B cells and was profoundly reduced in SMA animals. In adult human peripheral blood, dendritic cells and monocytes carried the highest SMN levels, yet adults with SMA still showed altered immune-cell composition and reduced immune-cell SMN expression.
Persistent peripheral immune changes in treated adults
The immune findings are striking because they appear in both treated and untreated patients. Adults receiving systemic or CNS-restricted therapy showed similar differences in immune-cell composition and SMN expression, and an exploratory untreated cohort did not show a strong treatment-specific effect relative to controls. In the commentary’s framing, this argues against a simple model in which standard SMN-directed treatment fully normalizes peripheral biology once motor function improves.
A single point stands out: motor rescue may coexist with incomplete molecular rescue.
Tapken, Rahmel-Stein, and colleagues observed reduced dendritic-cell frequencies and increased B-cell frequencies in SMA patients, alongside broader shifts in B, T, and NK-cell populations. Yeo places those findings into a mechanistic context by suggesting that some immune-cell subsets may have a higher intrinsic requirement for SMN than others. When SMN falls below a cell-specific threshold, splicing fidelity, RNA processing, and downstream immune development may all shift in ways that are not immediately visible at the bedside.
The commentary also draws attention to the differentiation state of the cell. Experiments in PMA-treated THP-1 cells showed enhanced aberrant SMN splicing and increased SMN-positive Cajal bodies after differentiation. That pattern suggests that functional demand for SMN may rise or change as immune cells mature, which could help explain why a uniform genetic defect creates uneven cellular consequences across the immune system.
Why SMN deficiency may affect immune development differently from motor neurons
Motor neurons became the classic model for selective vulnerability in SMA because they sit near a functional threshold for SMN deficiency. The commentary extends that logic to immune cells without collapsing the two systems into the same biology. Dendritic cells and monocytes may require more robust SMN-dependent RNA handling than other immune populations, while B cells in neonatal spleen may be particularly sensitive during early development.
Developmental timing may be decisive. In the neonatal mouse data, B-cell depletion, reduced dendritic cells, and expansion of neutrophils and macrophages suggest that early SMN loss can reshape hematopoiesis and lymphoid architecture before a patient ever reaches the treated era. Once those developmental programs are altered, later SMN replacement may improve some manifestations but leave others unchanged. In that sense, the immune system may record the disease history long after motor function begins to recover.
Yeo also connects these observations to prior work showing that SMN deficiency in hepatocytes can produce mitochondrial dysfunction and fatty-acid metabolic defects. Across tissues, the recurring pattern is not simply “low SMN equals disease.” The more accurate model is conditional vulnerability: how much SMN a cell needs, when it needs it, and what downstream damage follows once the threshold is crossed.
The bedside question is function, not phenotype alone
Immune-cell abnormalities are biologically interesting, but they are not yet clinically equivalent to immune disease. Yeo is careful on this point. Altered immune composition and reduced SMN do not by themselves prove infection susceptibility, vaccine failure, autoimmunity, or harmful inflammation in patients with SMA.
That caution should shape the next wave of studies. A meaningful trial of the immune consequences of SMA should not stop at phenotyping peripheral blood subsets. It should ask whether these abnormalities change vaccine responses, infection burden, lymphocyte function, inflammatory biomarkers, or the durability of clinical benefit over time. Longitudinal studies beginning before treatment would be especially valuable because they could separate developmental injury from reversible dysfunction and from abnormalities that are present but clinically silent.
For now, the most defensible interpretation is narrow but important: SMN restoration sufficient to rescue motor outcomes may still leave peripheral immune biology partially altered. Whether that residual biology is harmless, adaptive, or clinically important remains unknown.
Gene therapy adds another layer of immune complexity
The immune system is not only a target of SMN deficiency. It also shapes responses to adeno-associated virus gene therapy. Yeo points to evidence that infants with SMA can show immune exhaustion in CD8+ T cells before gene therapy and marked elevation afterward. That raises a practical challenge for systemic and vector-based therapies alike: the same immune defects that arise from SMA biology may also influence how patients respond to treatment.
This creates a difficult feedback loop. If the immune system is developmentally altered by SMN deficiency, then treatment given later may have to contend with a biology that has already drifted away from normal immune maturation. If immune cells also participate in responses to viral vectors or intrathecal therapies, then residual SMN deficiency could shape both safety and durability of treatment effects.
The commentary does not claim that these immune abnormalities have yet changed care. It does something more clinically useful: it forces the field to define what adequate SMN restoration actually means. For some tissues, survival may be enough. For others, especially the immune system, biochemical normalization may need to be deeper, earlier, or more sustained than current outcome measures reveal.
What remains unresolved is whether the persistent immune signatures described in treated SMA are developmental scars, ongoing consequences of partial SMN replacement, or incidental findings without clinical weight. The next studies will need to connect cell biology to patient outcomes before any of those explanations can be accepted as adequate.